Bringing the fundamentals into focus…
Back to Lakefront Biotherapeutics NV
How Lakefront Biotherapeutics NV stacks up
LKFT · against 403 other Healthcare companies of similar size
Valuation
96/ 100
Near the top of its peers.
Ranked #14 of 404 · scores higher than 96% of peers
Bars: peers in each 10-point band of the valuation score38 peers with a valuation score of 90–100, including LKFT · Click a bar to see the companies
Why valuation scores 96?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield, which is stronger than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -12.5% vs peer median 0.0%
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
- higher earnings for the price paid: stronger than 99% of peers. Earnings yield: 31.9% vs peer median 1.5%
Metric by metric
Position: dot = LKFT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LKFT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 392 reported | 31.9% | 1.7% | 100% | 30% | |
| EBITDA yieldHigher is better · 404 reported | Not reported | 4.3% | — | — | 50% |
| Free cash flow yieldHigher is better · 198 reported | -12.5% | -0.5% | 10% | 20% | |
| Book yieldHigher is better · 395 reported | Not reported | 34.6% | — | — | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around LKFTScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score